Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Yes, it is common for diarrhea and other GI side effects to show up in a predictable pattern roughly 24 to 48 hours after a Zepbound (tirzepatide) injection, since tirzepatide levels peak in that window and slow digestion, and the timing often improves as your body adjusts or after dose changes. That said, several factors influence whether your pattern is expected or a warning sign, including your current dose, recent dose escalations, hydration, fiber and fat intake, other medications, and whether symptoms last more than a day or two. Diarrhea that is severe, bloody, accompanied by fever, persistent vomiting, dizziness, or intense abdominal pain that radiates to your back is not routine and needs prompt medical attention. See below to understand the full timeline, self-care steps, and red flags you should not ignore.
Because "normal" side effects and early complications can feel similar in the first days after an injection, it is worth taking a free, instant, online symptom check to sort out what your specific symptoms suggest and what to do next.
Last reviewed for medical accuracy: 09/13/2026
Is it normal to get diarrhea only on the day after my Zepbound injection?
Many people taking Zepbound (semaglutide) wonder, “why does Zepbound cause diarrhea” and if it’s normal to have loose stools the day after the shot—but not before. Diarrhea is a known side effect of GLP-1 receptor agonists like Zepbound, and timing can vary from person to person. Below, we break down what you need to know, how Zepbound can lead to diarrhea, when it’s expected, and when to reach out for help.
Zepbound is a weekly injectable medication that mimics the hormone glucagon-like peptide-1 (GLP-1). It’s approved to help with chronic weight management in adults with obesity or overweight plus at least one weight-related condition (for example, high blood pressure or type 2 diabetes). By activating GLP-1 receptors in the brain and gut, Zepbound:
These effects together can improve blood sugar control and support weight loss.
Gastrointestinal (GI) side effects are among the most common complaints with GLP-1 agonists. Here’s why:
Because of these combined actions, diarrhea may occur, especially during dose increases or early in treatment.
It’s common to notice GI side effects at certain times in your dosing cycle, particularly:
So, if diarrhea happens consistently on the day after your Zepbound shot, it lines up with when the drug is most active in your system.
Clinical studies of semaglutide report varying rates of diarrhea, depending on dose and patient population:
Remember: everyone’s digestive system reacts a bit differently. Some people may never see diarrhea, while others experience it briefly.
If you’re asking, “why does Zepbound cause diarrhea?” and you’d like to stay on therapy, try these practical steps:
Most people find that GI side effects taper off after 4–8 weeks as they adapt to the medication.
Diarrhea alone is usually not dangerous, but you should contact your healthcare provider if you experience:
If you ever have symptoms that could be life-threatening or seriously affect your health, speak to a doctor right away or go to the nearest emergency department.
Not sure how serious your symptoms are? You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide if you need to talk to a healthcare professional and what steps to take next.
Understanding “why does Zepbound cause diarrhea” and how to handle it can help you stay on track with your treatment. Monitoring your symptoms and seeking guidance when needed will ensure you get the maximum benefit from Zepbound with as little discomfort as possible.
(References)
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. PMID: 34186022.
* Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ, SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. PMID: 34672967.
* Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179.
* Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7. Epub 2022 Sep 1. PMID: 36050763; PMCID: PMC9438179.
* Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM, SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.
* Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R, Fernández Landó L, Patel H. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023 Nov 7;330(17):1631-1640. doi: 10.1001/jama.2023.20294. PMID: 37786396; PMCID: PMC10548360.
* France NL, Syed YY. Tirzepatide: A Review in Type 2 Diabetes. Drugs. 2024 Feb;84(2):227-238. doi: 10.1007/s40265-023-01992-4. Epub 2024 Feb 23. PMID: 38388874.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.